Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:42 | H.C. Wainwright maintains Buy rating on Neumora stock ahead of obesity drug data | 11 | Investing.com | ||
01.10. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Host Virtual R&D Day on October 27 | 8 | GlobeNewswire (USA) | ||
16.09. | JPM downgrades Neumora, cites risk of more negative trial news | 29 | Investing.com | ||
08.08. | Elevidys sales weaken; Neumora gets into obesity | 7 | BioPharma Dive | ||
07.08. | Stifel maintains Hold rating on Neumora Therapeutics stock at $2.00 | 14 | Investing.com | ||
07.08. | Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215 | 6 | Seeking Alpha | ||
07.08. | Neumora Therapeutics GAAP EPS of -$0.33 | 4 | Seeking Alpha | ||
06.08. | Neumora Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
06.08. | Neumora Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
29.07. | Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating | 19 | Insider Monkey | ||
23.07. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 7 | GlobeNewswire (USA) | ||
16.07. | Mizuho raises Neumora Therapeutics stock price target on new drug candidate | 4 | Investing.com | ||
16.07. | Mizuho hebt Kursziel für Neumora Therapeutics nach Vorstellung neuen Wirkstoffkandidaten an | 25 | Investing.com Deutsch | ||
10.07. | H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock | 7 | Investing.com | ||
09.07. | Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 | 362 | GlobeNewswire (Europe) | NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits... ► Artikel lesen | |
30.05. | Neumora Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
16.05. | Neumora Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
12.05. | Neumora Therapeutics GAAP EPS of -$0.42 misses by $0.03 | 8 | Seeking Alpha | ||
12.05. | Neumora Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
12.05. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 466 | GlobeNewswire (Europe) | On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,30 | -1,47 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
CUREVAC | 4,608 | -0,56 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
AMGEN | 251,85 | -1,27 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
NOVAVAX | 7,128 | -2,16 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
BIOGEN | 127,00 | -0,24 % | Biogen Inc.: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality... ► Artikel lesen | |
MAINZ BIOMED | 1,490 | -0,67 % | Mainz Biomed reports on blood-based screening test for pancreatic cancer | ||
VIKING THERAPEUTICS | 29,065 | +7,47 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule
VK2735 Phase 1 Maintenance... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 21,420 | +1,18 % | Intellia (NTLA) Soars 13% to Fresh High | ||
TEMPUS AI | 75,00 | +2,04 % | AKTIONÄR-Tipp Tempus AI lässt Biotech-Aktie explodieren | Der Megatrend Künstliche Intelligenz (KI) ist an den Börsen weiter in aller Munde. Einer der großen Gewinner der Entwicklung: Tempus AI. Das Unternehmen will mit seinen KI-gestützten Lösungen die Präzisionsmedizin... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 6,234 | +2,26 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting | ||
BIOMARIN PHARMACEUTICAL | 46,590 | +1,33 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 18,590 | -3,98 % | Sarepta-Aktie: Zurück zu altem Glanz? | Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten... ► Artikel lesen | |
EXELIXIS | 31,890 | +2,64 % | Exelixis shares dip on colorectal cancer data | ||
CARDIOL THERAPEUTICS | 1,060 | +3,72 % | XFRA CT9: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCARDIOL THERAPEUTICS... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,691 | +6,96 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 |